Sucampo Pharmaceuticals, a developer of proprietary drugs based on prostones to treat constipation, priced its 3.75 million shares at $11.50 each, 23% below the midpoint of the proposed $14-$16 price range, on Thursday morning. Cowen & Company was the lead manager on the deal. The stock is expected to begin trading later on Thursday on the NASDAQ under the ticker "SCMP."
